Direct answer. Hepatitis A is an acute liver infection caused by HAV, a virus usually swallowed through contaminated food, water or close-contact exposure. It does not become a chronic infection. Most people recover, but severe illness and liver failure can occur. Suspected infection or a recent exposure needs appropriate clinical advice, rather than a liver supplement or a fixed home recovery timetable. CDC August 2025 original.
- Hepatitis A can spread before symptoms; good hygiene and exposure assessment matter.
- Symptoms can include jaundice, fatigue, nausea, dark urine and pale stools, but some people have none.
- Acute HAV blood testing is different from a test showing previous immunity.
- Supportive care and post-exposure prevention serve different purposes.
- Ask promptly about a recent exposure: the CDC prevention window is two weeks, not a reason to delay.
- Older adults, people with other liver disease and pregnant people need particular assessment.
Table of contents
- Evidence summary
- What hepatitis A is: acute infection without chronic HAV
- Stool-related spread, symptoms and exposure history
- Supportive treatment and prompt post-exposure prevention
- Food, fluids, alcohol and liver-supplement claims
- Acute-infection tests versus immunity results
- Jaundice, dehydration, bleeding and severe-illness warnings
- Pain medicines, prescriptions and supplements during illness
- Older adults, pregnancy, liver disease and weakened immunity
- Contact precautions, recovery review and practical planning
- Laboratory antiviral findings and clinical-benefit limits
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
| Question | Evidence role | Interpretation / confidence |
|---|---|---|
| Can hepatitis A become chronic? | Converging public clinical education | No. Longer symptoms or relapse does not mean a chronic HAV infection. |
| Can symptoms prove the diagnosis? | Original testing explanation | No. History and the appropriate laboratory pathway are needed. |
| Is there a specific antiviral home treatment? | Clinical care framework | No specific HAV treatment is established in this care source; support and assessment of severity matter. |
| What is the purpose of vaccination or immune globulin? | Prevention guidance | Prevent infection after selected exposures or before risk, rather than treat established acute illness. |
| Does the funding audit certify every vaccine study? | Financial-scope limit | No. Independent comparative efficacy and all original manufacturer chains were not cleared. |
Confidence is good in the virus distinctions, testing roles and urgency of the precautions described. Treatment statements explain attributed clinical care; they are not a newly conducted systematic review or financially cleared numerical efficacy ranking. An independently verified supplement replacement was not established. Public funding does not make every underlying drug or vaccine trial independent.
What hepatitis A is: acute infection without chronic HAV
Hepatitis A affects the liver and is caused by the hepatitis A virus. The word hepatitis means inflammation; other viruses and non-viral causes can also inflame the liver. A person with jaundice therefore needs assessment, rather than assuming that every episode is HAV. Virus-specific definition; Other causes and urgency.
HAV causes an acute infection. It does not persist as chronic hepatitis A in the way that hepatitis B or C can. Symptoms can nevertheless last longer than expected or return during recovery. That distinction matters: prolonged fatigue or recurrent symptoms need review, but do not by themselves establish a different virus or a chronic HAV carrier state. Acute versus relapsing illness.
Most people recover without lasting liver damage. Rare severe cases can cause liver failure and need hospital or specialist care. Older people and those with another liver condition can be more vulnerable to serious illness; a reassuring population description should not override worsening symptoms. Severe-illness context.
Stool-related spread, symptoms and exposure history
The main route is faecal–oral: a person unknowingly swallows virus from infected stool. Contaminated water, food handled by an infectious person and close contact can matter. Exposure during sex or shared drug use also needs a sensitive clinical history; the diagnosis is not a judgment about a person’s behaviour. Transmission explanation; Current exposure context.
Virus can spread before symptoms are recognised. A person who looks well may still be relevant to a contact investigation. Food safety and handwashing therefore matter alongside waiting for a diagnosis, and contacts should follow the health team’s advice rather than judging risk from appearance. Spread without symptoms.
Symptoms can include tiredness, nausea or vomiting, appetite loss, abdominal discomfort, fever, dark urine, pale stool and yellow eyes or skin. Many children and some adults have mild or no symptoms. The pattern overlaps with other illnesses, so a list of features cannot confirm the infection. Actual April 2026 symptom description.
Tell the clinician about recent travel, a known contact and possible food or water exposure. Infection can also occur without international travel. A country’s general incidence is not a diagnostic test and does not rule out a local exposure. Exposure and outbreak context.
Supportive treatment and prompt post-exposure prevention
The reviewed CDC care framework identifies supportive care rather than a specific HAV antiviral treatment. Clinicians may address nausea, pain, intake and complications, with hospital care for severe illness. The plan depends on the actual presentation; “usually recovers” is not an instruction to ignore deterioration. Attributed clinical care.
Post-exposure prevention has a different purpose: reducing the chance of infection after a recognised exposure. Contact a clinician or relevant public-health service promptly, even without symptoms. Under CDC’s US guidance, selected vaccine or immune-globulin prophylaxis should be assessed within two weeks after exposure. Do not wait until the end of that window. Original US timing and suitability framework.
The choice depends on age, previous vaccination or infection, immune state and other liver disease. Immune globulin provides short-term protection and may be used alongside vaccination in selected circumstances. This is a clinician-administered prevention pathway, not a personal dose or retail product recommendation. Different preventive roles.
Pre-travel vaccination is a separate consultation. US and UK routine eligibility policies differ, and children, infants and pregnant travellers need appropriate assessment. Ask before the trip about the destination, activities, previous doses and any medical condition; do not copy another country’s schedule. UK vaccination and travel context.
Food, fluids, alcohol and liver-supplement claims
Rest, adequate nutrition and suitable fluids can support recovery. If nausea or vomiting prevents intake, report it. General hydration advice is not a fixed drink volume for someone with other heart, kidney or liver problems, and it must not replace assessment of serious dehydration. Supportive-care advice; Intake-related warning signs.
Avoid alcohol during the illness and discuss medicines with the clinician or pharmacist. NIDDK specifically advises reviewing prescription, nonprescription and complementary products because some can damage the liver. A bottle sold for liver support is not automatically suitable during an acute infection. Ingredient-review precautions.
No independently verified human evidence for a supplement replacing HAV prevention or treating the infection was established in this source review. This does not mean that every possible supplement has been tested and failed. It means that no eligible replacement regimen is supported here. Nutritional help for poor intake has a different purpose from an antiviral claim.
Acute-infection tests versus immunity results
Assessment combines the symptoms and exposure history with appropriate blood testing. A liver enzyme result may show injury, but does not identify HAV by itself. An acute-infection test asks a different question from a result reflecting past infection or vaccination. Testing and immunity distinction.
The CDC diagnosis source identifies IgM anti-HAV as a marker used for acute infection, with test interpretation in the clinical context. IgG anti-HAV relates to previous exposure or immunity. Testing an asymptomatic person without an appropriate reason can create interpretation problems; a full report should be discussed rather than treating every positive antibody as newly infectious hepatitis. Original testing roles and precautions.
A vaccination history should be checked from records where possible. Previous HAV infection can provide immunity against HAV, but does not prevent unrelated hepatitis viruses. A combined A/B vaccine also does not treat established infection or establish protection against C, D or E. Immunity and separate-virus context.
Jaundice, dehydration, bleeding and severe-illness warnings
New jaundice needs urgent medical advice. Do not assume it is hepatitis A because a contact was infected. The NHS jaundice source notes that yellow skin or eyes can indicate a serious problem; appropriate investigation is needed. Urgent assessment.
Contact the clinical team about poor intake, reduced urination or persistent dizziness. Confusion, severe breathing difficulty or being difficult to wake can be emergency signs. A person need not match every item on a checklist to need urgent help. Current dehydration and shock warnings.
Vomiting blood needs medical help, including blood that resembles coffee grounds. Blood with faintness, confusion, black stool, rapid breathing or feeling generally unwell needs emergency assessment. Do not drive yourself. These signs must not be dismissed as an expected stage of HAV recovery. Bleeding triage.
A preventive injection and a symptom-relief medicine also have their own potential harms and contraindications. Discuss the actual formulation and medical history with the administering team. This guide does not calculate a personal vaccine risk or claim that every product is suitable for everyone.
Pain medicines, prescriptions and supplements during illness
Ask a pharmacist or clinician about painkillers and nausea medicines during liver illness. Do not assume a usual over-the-counter dose remains appropriate, or that all pain medicines must be stopped. The decision depends on the ingredient, existing prescriptions and clinical assessment. Current pain-medicine precaution.
Bring all herbal and nutritional products to the same review. Labels may contain several ingredients, and taking overlapping products can make assessment harder. Do not stop an essential prescription or add a claimed detoxification course without discussing the current illness. Prescription and complementary-product review.
Tell healthcare professionals about a suspected or confirmed infection before appointments. They can advise on infection precautions and whether the visit needs rearranging. For an emergency, explain the infection without delaying the call or necessary treatment. Care and contact precautions.
Older adults, pregnancy, liver disease and weakened immunity
The current NHS HAV page advises urgent contact when suspected infection occurs during pregnancy, in older people or in someone with a liver condition. These circumstances should be disclosed promptly. Ordinary travel or diet advice cannot determine the safety of waiting at home. Higher-risk assessment.
People with weakened immunity or chronic liver disease may need a different post-exposure prevention decision. CDC’s care source discusses additional preventive protection in selected exposed people; it does not supply a universal plan for every reader with the same diagnosis label. Special consideration after exposure.
Children need age-appropriate assessment and medicines. Mild symptoms in many children do not rule out infection or remove the need for contact advice. Do not give an adult prevention schedule, product or dose to a child based on this article. Age-related symptom context.
Contact precautions, recovery review and practical planning
Follow the local clinical/public-health instructions about work, school, nursery and food handling. Infectious periods and exclusion rules depend on the setting and symptom dates. This article does not replace those instructions with one global number of days. UK contact precautions.
Wash hands thoroughly with soap and water after using the toilet and before handling food. While infectious, do not prepare food or drinks for other people. Discuss close-contact precautions and contacts who may need prompt prevention advice with the treating service. Current hygiene and contact advice.
Ask who will review symptoms and any repeat blood tests, what would bring review forward and what recovery permits for work or activity. Fatigue can outlast the first symptoms; a fixed online date cannot determine when liver recovery is complete. Recovery and review context.
This guide supplies no personal prevention dose, painkiller limit, antiviral course or alcohol-resumption date. Keep the care plan and results accessible, and report continuing or recurrent symptoms rather than assuming either a cure or a chronic infection from how you feel.
Laboratory antiviral findings and clinical-benefit limits
Laboratory antiviral activity or an animal liver-protection finding does not establish treatment for acute HAV in humans. Useful studies would measure clinically meaningful illness, complications and harms in the actual population, with the comparator and financial chain clear. A lower enzyme value alone does not establish viral clearance. Manufacturer-funded or supplied-product efficacy is excluded from an independent benefit verdict.
Funding and source roles
Research funding at a glance
16 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The illness has no corporate owner or manufacturing country. Pharmaceutical and vaccine manufacturers, diagnostic suppliers, care providers and supplement sellers can earn income around prevention, diagnosis and treatment. The source audit below separates institutional income, permitted gift routes, outside-reviewer interests and original treatment evidence. Unknown allocation remains unknown; an interest is not an allegation of improper conduct.
A funding tier measures proximity to the subject; a credibility grade reflects transparency and accuracy incentives. Tier4 producer or commercially supported efficacy is excluded from an independent benefit verdict even when a source is free. Separate 2025–2026 disclosures do not establish payments for a December 2024 NIDDK page. The infographic summarises these disclosed relationships; it does not invent proportions of a page budget.
| Source | Funding / backers | Country / jurisdiction | Independence / credibility / gaps | Role in this article |
|---|---|---|---|---|
| NIDDK hepatitis A, December 2024 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. Credited outside reviewer: Paul Martin (University of Miami): own society profile declares past consultancy for AbbVie, Gilead, Merck and Mallinckrodt; disclosure period unclosed. These separate declarations do not prove a company funded the December 2024 NIDDK page; contemporaneous page compensation and original trial funds are unclosed. | United States federal education, Bethesda; credited reviewer location: Miami, Florida, United States; University of Miami. Local clinical and vaccine policies differ. | Tier 3 for relevant commercially connected outside reviewers; public institution separately identified. C provisional — actual December 2024 patient original checked for selected definitions, testing or care roles. Public educational accountability supports accuracy; simplification, credited reviewer interests and unclosed contemporaneous/trial finance limit independent efficacy use. No numerical treatment ranking or obsolete approval claim adopted. | Acute infection, testing, care, immunity and precautions; outside reviewer identified |
| NHS hepatitis A, April 24, 2026 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October 2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Symptoms, contact precautions and UK higher-risk assessment |
| CDC hepatitis A basics, August 29, 2025 | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; CDC Division of Viral Hepatitis, Atlanta; US clinical/public-health policy. | Tier 1 public education provisionally; original trial and individual contributor chains unclassified. B provisional — dated original body actually read. Public-health accuracy incentive, identifiable policy remit and source links; no complete author/donor/trial clearance. Brand comparisons, efficacy percentages, doses and worldwide schedule rules excluded. | Transmission before symptoms, clinical presentation and severe-illness context |
| CDC hepatitis A testing, January 11, 2024 | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; CDC Division of Viral Hepatitis, Atlanta; US clinical/public-health policy. | Tier 1 public education provisionally; original trial and individual contributor chains unclassified. B provisional — dated original body actually read. Public-health accuracy incentive, identifiable policy remit and source links; no complete author/donor/trial clearance. Brand comparisons, efficacy percentages, doses and worldwide schedule rules excluded. | Acute antibody/RNA context and limits of testing asymptomatic people |
| CDC hepatitis A clinical care, January 31, 2025 | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; CDC Division of Viral Hepatitis, Atlanta; US clinical/public-health policy. | Tier 1 public education provisionally; original trial and individual contributor chains unclassified. B provisional — dated original body actually read. Public-health accuracy incentive, identifiable policy remit and source links; no complete author/donor/trial clearance. Brand comparisons, efficacy percentages, doses and worldwide schedule rules excluded. | Supportive care and US post-exposure prevention context; doses and brands excluded |
| NHS jaundice, January 22, 2024 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October 2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Urgent assessment of new yellow eyes/skin |
| NHS vomiting blood, August 18, 2025 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October 2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Bleeding triage and emergency signs |
| NHS dehydration, May 1, 2026 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October 2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Poor-intake warning signs, serious dehydration and shock |
| NIDDK actual funding, gifts and location FAQ, May 2024 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. | United States; NIH/NIDDK, Bethesda, Maryland, with a Phoenix research branch; federal jurisdiction. | Tier 3 institutional financial self-disclosure. B provisional for actual appropriations, gift and location facts. FAQ/index review May 2024; actual21-page FY2027 justification printedNIDDK-6/8 separately labels FY2026 enacted, with mandatory type1-diabetes shown separately. The FY2027 request is not enacted finance; actual donors and page allocations unclosed. | Institutional provenance, not actual donor allocation |
| NIDDK budget/legislative index, May 2024 review, newer requests listed | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. | United States; NIH/NIDDK, Bethesda, Maryland, with a Phoenix research branch; federal jurisdiction. | Tier 3 institutional financial self-disclosure. B provisional for actual appropriations, gift and location facts. FAQ/index review May 2024; actual21-page FY2027 justification printedNIDDK-6/8 separately labels FY2026 enacted, with mandatory type1-diabetes shown separately. The FY2027 request is not enacted finance; actual donors and page allocations unclosed. | Proposals distinguished from actual appropriations |
| NIDDK actual FY2027 justification,21pages, containing separate FY2026 enacted table | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. | United States; NIH/NIDDK, Bethesda, Maryland, with a Phoenix research branch; federal jurisdiction. | Tier 3 institutional financial self-disclosure. B provisional for actual appropriations, gift and location facts. FAQ/index review May 2024; actual21-page FY2027 justification printedNIDDK-6/8 separately labels FY2026 enacted, with mandatory type1-diabetes shown separately. The FY2027 request is not enacted finance; actual donors and page allocations unclosed. | Institutional enacted funding, not hepatitis/page allocation; FY2027 request kept separate |
| NHS national website content and funding policy, October 2022 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October 2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national England patient-information service. | Tier 3 editorial/funding self-disclosure. B provisional — explicit funding and disclosure policy actually read. Dated 2022 policy, actual individual declarations and implementation not audited. | National website editorial/financial provenance |
| CDC actual FY2026 operating plan,4pages | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; Centers for Disease Control and Prevention, Atlanta, Georgia; federal jurisdiction. | Tier 3 financial, policy or contact self-disclosure. B provisional for actual original finance routes. Gift policy effective 2016, reviewed 2022; permission and conflict rules do not verify actual gifts, implementation or page allocations. | Whole programme budget, not a page/trial allocation |
| CDC original gift policy, effective 2016; reviewed 2022,24pages | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; Centers for Disease Control and Prevention, Atlanta, Georgia; federal jurisdiction. | Tier 3 financial, policy or contact self-disclosure. B provisional for actual original finance routes. Gift policy effective 2016, reviewed 2022; permission and conflict rules do not verify actual gifts, implementation or page allocations. | Direct gifts, foundation transfers and conflict-review requirements |
| CDC actual public-site contact/provenance | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; Centers for Disease Control and Prevention, Atlanta, Georgia; federal jurisdiction. | Tier 3 financial, policy or contact self-disclosure. B provisional for actual original finance routes. Gift policy effective 2016, reviewed 2022; permission and conflict rules do not verify actual gifts, implementation or page allocations. | Atlanta institutional location |
| Paul Martin original society financial declaration; period unclosed | Original AASLD profile declares past consultancy for AbbVie, Gilead, Merck and Mallinckrodt. Disclosure period, amounts, complete society backers and any NIDDK-page payment unresolved. | United States; AASLD society profile of University of Miami clinician. Full company ownership/backer chains not cleared. | Tier 3 subject-related author-interest self-disclosure. B provisional for the actual listed declarations; no inference of page sponsorship, improper conduct or a complete current financial audit. | Separate credited-reviewer interests only |
Frequently asked questions
Does hepatitis A become chronic?
No. Prolonged symptoms or relapse is not chronic HAV infection.
Can someone spread it before symptoms?
Yes. Contact assessment should not depend on whether someone looks ill.
Should I wait for jaundice after a possible exposure?
No. Ask promptly about prevention; the timing matters.
Does a positive antibody always mean a new infection?
No. Different antibodies and clinical circumstances have different meanings.
Will a liver supplement treat HAV?
No independently verified replacement was established here; discuss ingredients because liver injury can affect safety.
Are vaccination rules the same everywhere?
No. Local policy, age, exposure and medical history change the plan.
Sources and funding notes
- NIDDK hepatitis A, December 2024 — Acute infection, testing, care, immunity and precautions; outside reviewer identified.
- NHS hepatitis A, April 24, 2026 — Symptoms, contact precautions and UK higher-risk assessment.
- CDC hepatitis A basics, August 29, 2025 — Transmission before symptoms, clinical presentation and severe-illness context.
- CDC hepatitis A testing, January 11, 2024 — Acute antibody/RNA context and limits of testing asymptomatic people.
- CDC hepatitis A clinical care, January 31, 2025 — Supportive care and US post-exposure prevention context; doses and brands excluded.
- NHS jaundice, January 22, 2024 — Urgent assessment of new yellow eyes/skin.
- NHS vomiting blood, August 18, 2025 — Bleeding triage and emergency signs.
- NHS dehydration, May 1, 2026 — Poor-intake warning signs, serious dehydration and shock.
- NIDDK actual funding, gifts and location FAQ, May 2024 — Institutional provenance, not actual donor allocation.
- NIDDK budget/legislative index, May 2024 review, newer requests listed — Proposals distinguished from actual appropriations.
- NIDDK actual FY2027 justification,21pages, containing separate FY2026 enacted table — Institutional enacted funding, not hepatitis/page allocation; FY2027 request kept separate.
- NHS national website content and funding policy, October 2022 — National website editorial/financial provenance.
- CDC actual FY2026 operating plan,4pages — Whole programme budget, not a page/trial allocation.
- CDC original gift policy, effective 2016; reviewed 2022,24pages — Direct gifts, foundation transfers and conflict-review requirements.
- CDC actual public-site contact/provenance — Atlanta institutional location.
- Paul Martin original society financial declaration; period unclosed — Separate credited-reviewer interests only.
Actual December 2024 NIDDK hepatitis A, April 2026 NHS HAV, August 2025 CDC basics, January 2024 testing and January 2025 care bodies were read. Actual NHS urgent-safety sources and institutional funding/gift policies checked. Martin’s separate original society disclosure period is unclosed and is not assigned to the December 2024 page. NIDDK’s hand-sanitiser fallback, fixed contagious/recovery cutoffs, CDC brand/dose tables, universal vaccine schedules and numerical treatment effects are not adopted. Current primary patient guidance and the selected financial originals were read. Complete original treatment trials, their suppliers, society ownership/backer chains and contemporaneous page-review compensation were not audited. No personal dose, brand hierarchy or trial benefit percentage is supplied. ClinicalTrials.gov listings, institutional names and accreditation do not themselves establish safety or independence.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.